Title:
NOVEL SALT OF EMPAGLIFLOZIN DERIVATIVE, WHICH IS SGLT-2 INHIBITOR, AND HYDRATE OF SALT
Document Type and Number:
WIPO Patent Application WO/2022/065895
Kind Code:
A1
Abstract:
The present invention relates to a novel salt of an empagliflozin derivative and a hydrate of the salt, which have a relatively higher fusion point, solubility and melting point than those of empagliflozin, which is a drug developed as an SGLT-2 inhibitor, and thus exhibit improved physical and chemical properties, which is very suitable for formulation. In addition, a salt of a compound of chemical formula 1 prepared according to the present invention and a hydrate of the salt exhibit excellent pharmacokinetic characteristics as compared to empagliflozin, and thus are effective as SGLT-2 inhibitors.
Inventors:
JANG SUN-WOO (KR)
SUNG SI-YOUNG (KR)
SON BYOUNG-HWA (KR)
LIM HONG-GYU (KR)
KIM JUNG-SOO (KR)
TERMSARASAB UBONVAN (KR)
OH YUN-SEOK (KR)
KIM JI-HYEON (KR)
SUNG SI-YOUNG (KR)
SON BYOUNG-HWA (KR)
LIM HONG-GYU (KR)
KIM JUNG-SOO (KR)
TERMSARASAB UBONVAN (KR)
OH YUN-SEOK (KR)
KIM JI-HYEON (KR)
Application Number:
PCT/KR2021/013000
Publication Date:
March 31, 2022
Filing Date:
September 24, 2021
Export Citation:
Assignee:
DONG A ST CO LTD (KR)
International Classes:
C07H15/04; A61K31/7048
Domestic Patent References:
| WO2017203457A1 | 2017-11-30 | |||
| WO2018155970A1 | 2018-08-30 | |||
| WO2015099362A1 | 2015-07-02 |
Foreign References:
| KR20150138860A | 2015-12-10 | |||
| US20170247356A1 | 2017-08-31 | |||
| CN105524033A | 2016-04-27 | |||
| CN105769803A | 2016-07-20 | |||
| KR102111248B1 | 2020-05-14 |
Attorney, Agent or Firm:
ROH, Jae-Chull (KR)
Download PDF:
Previous Patent: NOVEL QUINAZOLINE DERIVATIVE HAVING FLT3 INHIBITORY ACTIVITY, AND USE THEREOF
Next Patent: FOLDABLE ELECTRONIC DEVICE
Next Patent: FOLDABLE ELECTRONIC DEVICE